CA2992221C - Mdm2 inhibitors and combinations thereof - Google Patents
Mdm2 inhibitors and combinations thereof Download PDFInfo
- Publication number
- CA2992221C CA2992221C CA2992221A CA2992221A CA2992221C CA 2992221 C CA2992221 C CA 2992221C CA 2992221 A CA2992221 A CA 2992221A CA 2992221 A CA2992221 A CA 2992221A CA 2992221 C CA2992221 C CA 2992221C
- Authority
- CA
- Canada
- Prior art keywords
- combination
- compound
- inhibitor
- cancer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012819 MDM2-Inhibitor Substances 0.000 title claims abstract description 79
- 238000011282 treatment Methods 0.000 claims abstract description 143
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 102
- 229940083338 MDM2 inhibitor Drugs 0.000 claims abstract description 74
- 239000003814 drug Substances 0.000 claims abstract description 67
- 201000011510 cancer Diseases 0.000 claims abstract description 66
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims description 71
- 150000003839 salts Chemical class 0.000 claims description 70
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 63
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 37
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 19
- 229960001183 venetoclax Drugs 0.000 claims description 19
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 11
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229940124647 MEK inhibitor Drugs 0.000 abstract description 60
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract description 59
- 238000000034 method Methods 0.000 abstract description 30
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract description 5
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 289
- 150000001875 compounds Chemical class 0.000 description 269
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 132
- 230000005764 inhibitory process Effects 0.000 description 72
- 239000003795 chemical substances by application Substances 0.000 description 62
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 60
- 229960004066 trametinib Drugs 0.000 description 58
- 206010009944 Colon cancer Diseases 0.000 description 51
- 102000047934 Caspase-3/7 Human genes 0.000 description 49
- 108700037887 Caspase-3/7 Proteins 0.000 description 49
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 46
- 229940079593 drug Drugs 0.000 description 45
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 33
- 230000006907 apoptotic process Effects 0.000 description 29
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 238000010790 dilution Methods 0.000 description 27
- 239000012895 dilution Substances 0.000 description 27
- 230000006698 induction Effects 0.000 description 27
- 210000004940 nucleus Anatomy 0.000 description 25
- 230000004044 response Effects 0.000 description 25
- 230000002195 synergetic effect Effects 0.000 description 25
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 22
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 21
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 21
- 239000013642 negative control Substances 0.000 description 21
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 21
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 21
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 20
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 20
- 229940121647 egfr inhibitor Drugs 0.000 description 20
- 230000035772 mutation Effects 0.000 description 19
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 17
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 17
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 16
- 239000012828 PI3K inhibitor Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 238000000386 microscopy Methods 0.000 description 16
- 239000013641 positive control Substances 0.000 description 16
- 102100030708 GTPase KRas Human genes 0.000 description 15
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 15
- 230000004663 cell proliferation Effects 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 230000000431 effect on proliferation Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 description 14
- 230000006882 induction of apoptosis Effects 0.000 description 14
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 13
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 229940125431 BRAF inhibitor Drugs 0.000 description 11
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 11
- 230000010261 cell growth Effects 0.000 description 11
- 238000011284 combination treatment Methods 0.000 description 11
- 238000001493 electron microscopy Methods 0.000 description 11
- 229960001433 erlotinib Drugs 0.000 description 11
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 11
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 10
- -1 RDEA436 Chemical compound 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000002508 compound effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 230000005284 excitation Effects 0.000 description 10
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 10
- WWWTWPXKLJTKPM-UHFFFAOYSA-N 2-aminooxyethanol Chemical compound NOCCO WWWTWPXKLJTKPM-UHFFFAOYSA-N 0.000 description 9
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 9
- 239000010432 diamond Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 8
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000005754 cellular signaling Effects 0.000 description 8
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 8
- 229960002465 dabrafenib Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 7
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 7
- 108091007960 PI3Ks Proteins 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 description 6
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 description 6
- 230000005723 MEK inhibition Effects 0.000 description 6
- 230000003044 adaptive effect Effects 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000890 drug combination Substances 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 5
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 5
- 108091008794 FGF receptors Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000204031 Mycoplasma Species 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 229960001686 afatinib Drugs 0.000 description 5
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 238000000611 regression analysis Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 4
- 241000282320 Panthera leo Species 0.000 description 4
- 241001499740 Plantago alpina Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000010293 colony formation assay Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000012050 conventional carrier Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002584 gefitinib Drugs 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000000861 pro-apoptotic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000011885 synergistic combination Substances 0.000 description 4
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical group N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 3
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 3
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 description 3
- 206010069755 K-ras gene mutation Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229950004847 navitoclax Drugs 0.000 description 3
- 229950008835 neratinib Drugs 0.000 description 3
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 241001415342 Ardea Species 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 239000005461 Canertinib Substances 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 101001108197 Homo sapiens NADPH oxidase activator 1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 102100021882 NADPH oxidase activator 1 Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229950008001 matuzumab Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229950006299 pelitinib Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- CSGQVNMSRKWUSH-IAGOWNOFSA-N (3r,4r)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol Chemical compound COC1=CC=CC(NC=2C3=C(CN4C[C@@H](O)[C@H](N)CC4)C=CN3N=CN=2)=C1 CSGQVNMSRKWUSH-IAGOWNOFSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- LOROIKRUMJLRJU-UHFFFAOYSA-N 4,6-dihydro-1h-pyrrolo[2,3-d]imidazol-5-one Chemical class N1C=NC2=C1CC(=O)N2 LOROIKRUMJLRJU-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- UIYYKSUHRZUEQP-VIFPVBQESA-N 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-n-[(2s)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOC[C@H](C)O)C=C(F)C(=O)N1C UIYYKSUHRZUEQP-VIFPVBQESA-N 0.000 description 1
- 101150023956 ALK gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241001212017 Brana Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000012609 Cowden disease Diseases 0.000 description 1
- 201000002847 Cowden syndrome Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 230000037060 G2 phase arrest Effects 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 230000036197 S-phase depletion Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710183263 Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220350613 c.214A>G Human genes 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000006385 lung benign neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000010700 sporadic breast cancer Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229950003046 tesevatinib Drugs 0.000 description 1
- HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940083090 trametinib 2 mg Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211080P | 2015-08-28 | 2015-08-28 | |
| US62/211,080 | 2015-08-28 | ||
| US201562243337P | 2015-10-19 | 2015-10-19 | |
| US62/243,337 | 2015-10-19 | ||
| US201562250574P | 2015-11-04 | 2015-11-04 | |
| US62/250,574 | 2015-11-04 | ||
| PCT/IB2016/055050 WO2017037579A1 (en) | 2015-08-28 | 2016-08-24 | Mdm2 inhibitors and combinations thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2992221A1 CA2992221A1 (en) | 2017-03-09 |
| CA2992221C true CA2992221C (en) | 2023-06-27 |
Family
ID=56877086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2992221A Active CA2992221C (en) | 2015-08-28 | 2016-08-24 | Mdm2 inhibitors and combinations thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20190060309A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4241850A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018528206A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180041677A (cg-RX-API-DMAC7.html) |
| CN (2) | CN111821306A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016314082B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2992221C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2962460T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL257015B (cg-RX-API-DMAC7.html) |
| RU (2) | RU2020142739A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017037579A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| US11672801B2 (en) | 2016-10-19 | 2023-06-13 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11285154B2 (en) | 2017-03-29 | 2022-03-29 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating cancer |
| WO2018178925A1 (en) * | 2017-03-31 | 2018-10-04 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
| WO2019040511A1 (en) * | 2017-08-22 | 2019-02-28 | University Of Maryland Batimore | DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS |
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| EP3694518A1 (en) * | 2017-10-12 | 2020-08-19 | Novartis AG | Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers |
| US12053454B2 (en) * | 2017-12-31 | 2024-08-06 | Evergreen Biosciences | Compositions for cryopreservation and methods of use thereof |
| US11639355B2 (en) | 2018-03-12 | 2023-05-02 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors |
| CA3092307A1 (en) * | 2018-03-20 | 2019-09-26 | Novartis Ag | Pharmaceutical combinations |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| AU2019314819A1 (en) | 2018-07-31 | 2020-10-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CA3092753C (en) | 2018-07-31 | 2023-10-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab |
| UA126098C2 (uk) * | 2018-07-31 | 2022-08-10 | Есентейдж Фарма (Сучжоу) Ко., Лтд. | КОМБІНОВАНИЙ ПРОДУКТ НА ОСНОВІ ІНГІБІТОРА Bcl-2 ТА ІНГІБІТОРА MDM2 ТА ЙОГО ЗАСТОСУВАННЯ В ПОПЕРЕДЖЕННІ ТА/АБО ЛІКУВАННІ ЗАХВОРЮВАНЬ |
| MX2021007391A (es) * | 2018-12-20 | 2021-09-23 | Novartis Ag | Regimenes de baja dosis extendida para inhibidores de mdm2. |
| WO2021018032A1 (en) * | 2019-07-26 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease |
| TWI772992B (zh) * | 2019-12-03 | 2022-08-01 | 大陸商蘇州亞盛藥業有限公司 | 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物 |
| TW202200147A (zh) * | 2020-05-26 | 2022-01-01 | 韓商韓美藥品股份有限公司 | Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療 |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| JP2024157057A (ja) * | 2021-06-29 | 2024-11-07 | 国立大学法人 東京大学 | バレット食道の治療用組成物 |
| CN117562907B (zh) * | 2023-11-17 | 2025-08-22 | 广州医科大学 | 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
| UA77765C2 (en) | 2002-03-13 | 2007-01-15 | Array Biopharma Inc | N3 alkylated derivatives of benzimidazole as mek inhibitors |
| CA2569850C (en) | 2004-06-11 | 2011-04-05 | Toshiyuki Sakai | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer |
| BRPI0610139A2 (pt) | 2005-05-18 | 2010-06-01 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de uso dos mesmos |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2370566A1 (en) * | 2008-12-03 | 2011-10-05 | Università Degli Studi Di Torino | Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8859535B2 (en) * | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| US20140348819A1 (en) * | 2011-06-24 | 2014-11-27 | Dana-Farber Cancer Institute, Inc. | Methods of Treating Cancer |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| EP2752191A1 (en) * | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| KR102305351B1 (ko) * | 2013-11-11 | 2021-09-24 | 암젠 인크 | 암의 치료를 위한, mdm2 억제제 및 하나 이상의 추가적 약제학적 활성 제제를 포함하는 조합 요법 |
| TW201605450A (zh) * | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| WO2015095834A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using erk1/2 and bcl-2 family inhibitors |
| AU2014372166B2 (en) | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
-
2016
- 2016-08-24 US US15/756,094 patent/US20190060309A1/en not_active Abandoned
- 2016-08-24 RU RU2020142739A patent/RU2020142739A/ru unknown
- 2016-08-24 WO PCT/IB2016/055050 patent/WO2017037579A1/en not_active Ceased
- 2016-08-24 RU RU2018110770A patent/RU2740091C2/ru active
- 2016-08-24 CA CA2992221A patent/CA2992221C/en active Active
- 2016-08-24 EP EP23177095.9A patent/EP4241850A3/en not_active Withdrawn
- 2016-08-24 CN CN202010783071.9A patent/CN111821306A/zh not_active Withdrawn
- 2016-08-24 AU AU2016314082A patent/AU2016314082B2/en not_active Ceased
- 2016-08-24 EP EP16760803.3A patent/EP3340989B1/en not_active Revoked
- 2016-08-24 KR KR1020187005360A patent/KR20180041677A/ko not_active Ceased
- 2016-08-24 CN CN201680062336.8A patent/CN108348520A/zh active Pending
- 2016-08-24 ES ES16760803T patent/ES2962460T3/es active Active
- 2016-08-24 JP JP2018510877A patent/JP2018528206A/ja active Pending
-
2018
- 2018-01-18 IL IL257015A patent/IL257015B/en unknown
-
2019
- 2019-07-09 AU AU2019204938A patent/AU2019204938B2/en not_active Ceased
-
2020
- 2020-09-09 IL IL277239A patent/IL277239B/en unknown
- 2020-11-17 JP JP2020190870A patent/JP2021042222A/ja active Pending
-
2021
- 2021-03-01 US US17/188,726 patent/US20210260059A1/en not_active Abandoned
-
2023
- 2023-01-13 US US18/154,717 patent/US20230398115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019204938B2 (en) | 2020-07-16 |
| EP3340989B1 (en) | 2023-08-16 |
| RU2018110770A3 (cg-RX-API-DMAC7.html) | 2020-01-15 |
| RU2020142739A (ru) | 2021-01-15 |
| US20230398115A1 (en) | 2023-12-14 |
| US20210260059A1 (en) | 2021-08-26 |
| AU2016314082B2 (en) | 2019-07-25 |
| EP3340989A1 (en) | 2018-07-04 |
| JP2021042222A (ja) | 2021-03-18 |
| CN111821306A (zh) | 2020-10-27 |
| EP4241850A2 (en) | 2023-09-13 |
| RU2018110770A (ru) | 2019-09-30 |
| AU2016314082A1 (en) | 2018-02-08 |
| US20190060309A1 (en) | 2019-02-28 |
| AU2019204938A1 (en) | 2019-07-25 |
| ES2962460T3 (es) | 2024-03-19 |
| KR20180041677A (ko) | 2018-04-24 |
| RU2020142739A3 (cg-RX-API-DMAC7.html) | 2021-05-20 |
| IL257015A (en) | 2018-03-29 |
| IL257015B (en) | 2022-02-01 |
| CA2992221A1 (en) | 2017-03-09 |
| CN108348520A (zh) | 2018-07-31 |
| RU2740091C2 (ru) | 2021-01-11 |
| JP2018528206A (ja) | 2018-09-27 |
| EP4241850A3 (en) | 2023-11-08 |
| IL277239B (en) | 2022-04-01 |
| WO2017037579A1 (en) | 2017-03-09 |
| IL277239A (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230398115A1 (en) | Mdm2 inhibitors and combinations thereof | |
| KR102258698B1 (ko) | B-Raf 억제제와 제2 억제제를 포함하는 조합 요법 | |
| JP2019532051A (ja) | Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ | |
| AU2013343425A1 (en) | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases | |
| RU2739992C2 (ru) | Композиции апилимода и способы их применения в лечении колоректального рака | |
| US20160129003A1 (en) | Pharmaceutical Combinations | |
| WO2012059526A1 (en) | Treatment of mastocytosis with masitinib | |
| EP4106756A1 (en) | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| WO2018092064A1 (en) | Combinations of mdm2 inhibitors and bcl-xl inhibitors | |
| WO2017037586A1 (en) | Combination therapy using pi3k inhbitor and mdm2 inhibitor | |
| CN111163781B (zh) | 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合 | |
| HK1248605A1 (en) | Mdm2 inhibitors and combinations thereof | |
| HK1248605B (en) | Mdm2 inhibitors and combinations thereof | |
| RU2774612C2 (ru) | Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk | |
| HK40051622A (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
| US20180256557A1 (en) | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210823 |
|
| EEER | Examination request |
Effective date: 20210823 |
|
| EEER | Examination request |
Effective date: 20210823 |
|
| EEER | Examination request |
Effective date: 20210823 |
|
| EEER | Examination request |
Effective date: 20210823 |
|
| EEER | Examination request |
Effective date: 20210823 |
|
| EEER | Examination request |
Effective date: 20210823 |